Conte Santina, Lagacé François, Ghazawi Feras M, Cattelan Leila, Nath Siddharth, Dhillon Jobanpreet, Nedjar Hacene, Rahme Elham, Sasseville Denis, Burnier Miguel N, Litvinov Ivan V
Faculty of Medicine and Health Sciences, McGill University, Montréal, QC, Canada.
Division of Dermatology, McGill University, Montréal, QC, Canada.
Front Med (Lausanne). 2023 Jan 24;9:1001799. doi: 10.3389/fmed.2022.1001799. eCollection 2022.
BACKGROUND/AIMS: Uveal melanoma is the most common type of non-cutaneous melanoma and the most common ocular malignancy in the adult population, especially affecting Caucasians (98% of cases). Despite its low incidence rate, we have noted increasing incidence trends in recent years.
We analyzed uveal melanoma incidence data using the Canadian Cancer Registry (CCR) for 2011-2017 years. The data was examined using the International Classification of Diseases for Oncology, Third Edition, codes for all uveal melanoma subtypes. The data for 2011-2017 was then compared to previously published work by our research group for uveal melanoma incidence in Canada between 1992 and 2010 using the same methodology.
Between 2011 and 2017, 1,215 patients were diagnosed with uveal melanoma, 49% of whom were females. The percentage distribution of uveal melanoma between the sexes was similar between 1992-2010 and 2011-2017, whereby of the 2,215 diagnoses of uveal melanoma in 1992-2010, 47.9% were females. The change in the incidence rate for this cancer has doubled between 1992-2010 and 2011-2017, from 0.074 to 0.15 cases per million individuals per year. Our study documents that the Canadian 2011-2017 age-standardized incidence rate (ASIR) for uveal melanoma against the World Health Organization (WHO) 2000-2025 world population standard was 5.09 cases per million individuals per year (95% confidence interval, 4.73-5.44), as compared with the 1992-2010 rate of 3.34 cases per million individuals per year (95% confidence interval, CI 3.20 to 3.47).
This work demonstrates an ongoing, steady increase in uveal melanoma incidence in Canada in recent years.
背景/目的：葡萄膜黑色素瘤是最常见的非皮肤黑色素瘤类型，也是成年人群中最常见的眼部恶性肿瘤，尤其在白种人中更为常见（占病例的98%）。尽管其发病率较低，但近年来我们注意到其发病率呈上升趋势。
我们使用加拿大癌症登记处（CCR）分析了2011 - 2017年的葡萄膜黑色素瘤发病率数据。数据采用国际肿瘤疾病分类第三版中所有葡萄膜黑色素瘤亚型的编码进行检查。然后，使用相同方法将2011 - 2017年的数据与我们研究小组之前发表的关于1992年至2010年加拿大葡萄膜黑色素瘤发病率的研究进行比较。
2011年至2017年期间，有1215例患者被诊断为葡萄膜黑色素瘤，其中49%为女性。1992 - 2010年和2011 - 2017年期间，葡萄膜黑色素瘤在两性之间的百分比分布相似，在1992 - 2010年的2215例葡萄膜黑色素瘤诊断病例中，47.9%为女性。该癌症的发病率在1992 - 2010年至2011 - 2017年期间翻了一番，从每年每百万人口0.074例增至0.15例。我们的研究表明，按照世界卫生组织（WHO）2000 - 2025年世界人口标准，2011 - 2017年加拿大葡萄膜黑色素瘤的年龄标准化发病率（ASIR）为每年每百万人口5.09例（95%置信区间，4.73 - 5.44），而1992 - 2010年的发病率为每年每百万人口3.34例（95%置信区间，CI 3.20至3.47）。
这项研究表明，近年来加拿大葡萄膜黑色素瘤的发病率持续稳步上升。
